HCG and TRT: Why Doctors Add HCG to Testosterone Therapy

When men start testosterone replacement therapy, many quickly discover an unexpected conversation with their doctor: should you also take HCG? Human chorionic gonadotropin has become one of the most frequently discussed add-on therapies in TRT clinics, but it isn't necessary for everyone. Understanding what HCG does, who benefits from it, and what the evidence says helps you have a more informed discussion before your next prescription.

What Is HCG?

Human chorionic gonadotropin is a hormone naturally produced during pregnancy. In men, it mimics luteinizing hormone (LH), the signal your pituitary gland sends to your testicles to produce testosterone and sperm. Because HCG binds to the same LH receptors on Leydig cells, it can stimulate testicular function even when your natural LH production has been suppressed by exogenous testosterone.

This is the key mechanism that makes HCG useful during TRT. When testosterone replacement shuts down your HPTA axis (hypothalamic-pituitary-testicular axis), HCG can substitute for the missing LH signal and keep your testicles working despite the external testosterone suppressing your own hormone production.

Why TRT Clinics Prescribe HCG

Clinical practices vary, but the most common reasons providers add HCG to a TRT protocol fall into four categories:

Preserving Fertility

The most evidence-supported use of HCG alongside TRT is maintaining sperm production. TRT alone suppresses spermatogenesis in most men, often reducing sperm counts to contraceptive levels within 3 to 6 months. HCG can counteract this suppression by providing the gonadotropin signal required for spermatogenesis. A 2019 study published in the Journal of Urology found that men receiving TRT with concomitant HCG maintained significantly higher sperm counts than those on TRT alone, and some men maintained counts sufficient for natural conception.

Importantly, HCG is not a guaranteed fertility preservation strategy. Results vary based on dose, frequency, baseline testicular function, and individual biology. Men for whom fertility is an immediate priority should discuss alternative approaches such as enclomiphene therapy or planned sperm banking with their provider.

Maintaining Testicular Volume

Testicular atrophy is one of the most commonly reported physical changes men notice on TRT. The testes shrink because the primary stimulus for their size and function (LH and FSH) has been withdrawn. HCG provides that stimulus and can help maintain testicular volume during testosterone therapy.

While testicular atrophy is a cosmetic and psychological concern for many men rather than a medical risk, some providers and patients consider it significant enough to justify the added cost and complexity of HCG injections. Research published in Clinical Endocrinology has documented that HCG co-therapy can largely prevent the testicular volume loss associated with TRT monotherapy.

Improving Well-being on TRT

Some men report feeling better on TRT when HCG is included, even when infertility is not a concern. The mechanism may involve intratesticular testosterone production, as HCG stimulates the testes to produce testosterone internally. Systemic testosterone levels from external injections and intratesticular testosterone are not identical in their tissue distribution, and some researchers hypothesize that maintaining testicular function provides additional benefits.

The evidence for this is more anecdotal than clinical. Small studies and patient surveys in reproductive medicine journals have found subjective improvements in mood, energy, and sexual function when HCG is added, but the data are not robust enough to recommend HCG universally for this purpose alone.

Avoiding Low Estradiol Symptoms

In some men, HCG can increase the production of estradiol through aromatization of intratesticular testosterone. For patients who experience low estradiol symptoms on TRT (joint pain, poor sleep, low libido), the additional estradiol from HCG may be beneficial. Conversely, in men who are already sensitive to estradiol elevation or prone to gynecomastia, HCG may worsen symptoms. This is a clinical judgment your provider makes based on your labs and response.

HCG Monotherapy: An Alternative to TRT

HCG is sometimes used as a standalone treatment for hypogonadism rather than combined with testosterone. In HCG monotherapy, the hormone stimulates the patient's own Leydig cells to produce testosterone, preserving the natural production pathway rather than replacing it externally.

This approach is particularly attractive for younger men and those who want to preserve fertility. A study in the International Journal of General Medicine found that HCG monotherapy significantly increased both serum testosterone and sperm counts in men with secondary hypogonadism. However, HCG monotherapy requires intact testicular function and is not effective for men with primary testicular failure.

Typical HCG Protocols Used with TRT

Protocol details and dosing information should come from your prescribing physician. Typical clinical practice involves subcutaneous or intramuscular injection of HCG at frequencies ranging from two to three times weekly, with doses adjusted based on symptoms, serum testosterone levels, and estradiol levels. Your provider will individualize this based on your labs and goals.

Common protocols seen in published clinical practice include HCG dosing two to three times per week alongside the patient's standard TRT protocol. Blood work at regular intervals is essential because HCG can significantly increase both testosterone and estradiol levels.

Side Effects and Risks of HCG

HCG is not without risks. The most clinically significant concern is elevated estradiol. Because HCG stimulates intratesticular testosterone production, and high levels of intratesticular testosterone can aromatize to estradiol, some men experience significant estrogen elevation on HCG co-therapy. Symptoms can include gynecomastia (breast tissue enlargement), water retention, mood changes, and increased emotional sensitivity.

Other reported side effects include injection site reactions, acne or oily skin due to increased androgen production, and potential exacerbation of existing prostate conditions. As with any hormonal therapy, men with a history of hormone-sensitive cancers should discuss these risks thoroughly with their provider.

HCG also introduces additional cost and injection burden. Depending on the supplier and dose, monthly HCG costs can range from $30 to $150 or more, which may not be covered by all insurance plans when prescribed alongside TRT.

Who Should Consider Adding HCG to Their TRT

The strongest cases for HCG co-therapy include: men who want to preserve fertility during TRT; men experiencing testicular atrophy and who consider it clinically significant; men whose estradiol runs low on TRT monotherapy and who have low-estradiol symptoms; and younger men (under 35) who may benefit from maintaining endogenous testicular function.

Men for whom HCG may be unnecessary include: those who do not plan to father children and have no concern about testicular volume; men already experiencing high estradiol symptoms on TRT; men with contraindications to additional hormonal therapy; and those for whom the cost and injection burden outweighs perceived benefits.

What to Monitor When Taking HCG with TRT

When HCG is added to a TRT protocol, the standard monitoring panel should include total and free testosterone, estradiol (sensitive assay), LH, FSH, complete blood count (to monitor for erythrocytosis, which HCG may exacerbate), prostate-specific antigen, and a comprehensive metabolic panel. In men concerned with fertility, semen analysis at baseline and at intervals after starting HCG provides the most direct measure of the therapy's impact on sperm production.

The frequency of monitoring typically mirrors standard TRT protocols: baseline labs, follow-up at 4 to 6 weeks after starting or adjusting HCG, and then every 3 to 6 months once stable. Your provider will adjust the schedule based on your individual response.

HCG vs. Enclomiphene: A Key Distinction

Both HCG and enclomiphene aim to preserve testicular function during testosterone therapy, but they work through fundamentally different mechanisms. Enclomiphene stimulates the pituitary to produce its own LH and FSH, keeping the entire native HPTA axis functioning. HCG bypasses the pituitary entirely and directly stimulates the testicles.

In practice, enclomiphene is more appropriate for men with a functioning pituitary who want a fully endogenous replacement strategy, while HCG is more versatile and works even when the pituitary is suppressed by external testosterone. Many TRT providers who prescribe both report that HCG is more effective at maintaining sperm counts, while enclomiphene may feel more natural since it preserves the body's own signaling cascade.

The Bottom Line

HCG is a well-established adjunct to TRT with clear clinical applications for fertility preservation and maintaining testicular function. The evidence supports its use for specific, identified indications rather than as a universal addition to every TRT protocol. The decision should be based on your clinical profile, goals, and laboratory values, made in consultation with a qualified healthcare provider.

Whether you need HCG, enclomiphene, TRT monotherapy, or an alternative approach altogether, the most important step is comprehensive blood work and a thorough discussion with a provider who understands both the endocrinology and the practical implications of these treatments.